Participants 556 610 6
376 patients with newly diagnosed CML in chronic phase
Participants 636 687 7
340 patients were Ph/BCR-ABL positive and evaluable
Participants 949 1028 7
534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU)
Participants 1639 1651 3
534 patients
Participants 1653 1662 3
105 (20%)
